31 results
6-K
CNTB
Connect Biopharma Holdings Limited
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
to an open label Q2W rademikibart arm (n=86).
An efficacy analysis in patients that achieved Investigator’s Global Assessment scale (“IGA”) 0/1 or Eczema
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Limited
23 Jun 23
House Lease Contract
4:31pm
the relevant formalities for project approval and pass the environmental impact assessment), except for R&D experiments, no hazardous chemicals (including
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Limited
5 Jun 23
Current report (foreign)
4:28pm
involvement; EASI=eczema area and severity Index; IGA=investigator global assessment; LOCF=last observation carried forward; LS=least squares; Q2W=every 2 … -90=at least 50%, 75%, and 90% decreases from baseline; IGA=investigator’s global assessment; LD= loading dose.; PP-NRS=peak pruritus numeric rating
6-K
EX-99.2
5i8ti2j8jzxdvi4
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.1
graj87hryl7rqp1a7x
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
5h8r7layy0gkj3wr
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
EX-1.2
malugv
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
5wn2 pi4w0ezm71cv7mj
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.12
7lwn74
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.13
zdw6tfhh 8r2hqkk
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
jzlastff y48v
5 Jan 22
Current report (foreign)
5:24pm
6-K
8im1k kdqr3je8w6
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.2
9esum
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
3qgi224m
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
b1842ihb
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.2
zzgk2zt yrvm
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
424B4
onj5cul66tyavp2
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
x5ev6 ttnmvsve
18 Mar 21
Registration statement (foreign) (amended)
6:15am